South Korean Ministry of Health's Lee Hae-hee On Partnership With AstraZeneca To Bolster Domestic Firms' Global Aspirations: An Interview With PharmAsia News.
This article was originally published in PharmAsia News
Executive Summary
SEOUL - AstraZeneca Plc. signed a memorandum of understanding with South Korea's Ministry of Health and Welfare April 4 to commit to an R&D investment of KRW 80 billion ($73.48 million) in Korea through the next five years. The company also agreed to provide training and information exchanges to Korea's pharma industry, which is looking for inroads into foreign markets. The MOU is a follow-up to an MOU signed between the two parties in 2006. Lee Hae-hee, healthcare R&D assistant director at South Korea's Ministry of Health and Welfare, discussed the deal - announced in early April - with PharmAsia News on the sidelines of Medical Korea.